Mon, 27 May 2024 Today's Paper

AstraZeneca vaccine: Denmark stops rollout completely

15 April 2021 09:42 am - 3     - {{hitsCtrl.values.hits}}


Denmark has ceased giving the Oxford-AstraZeneca Covid vaccine amid concerns about rare cases of blood clots, the first European country to do so fully.

The move is expected to delay the country's vaccination programme by several weeks.

Drug watchdog the European Medicines Agency last week announced a possible link with clots but said the risk of dying of Covid-19 was much greater.

Several European countries had previously briefly suspended the jab.

Most have now resumed vaccinations with AstraZeneca, but often with limits to older age groups.

On Tuesday, the US, Canada and the European Union paused the Johnson & Johnson vaccine for similar reasons over clotting.

South Africa has also paused its use, despite the Johnson & Johnson being its preferred vaccine because of its effectiveness against the South African variant.

For both AstraZeneca and Johnson & Johnson, the blood clot side effects are extremely rare.

The EU's vaccine roll-out has been criticised by the World Health Organization (WHO) for being too slow, and there are concerns this latest delay could throw it into further turmoil.

Both vaccines work by a similar method, known as adenoviral vectors. (BBC)

  Comments - 3

  • Selvakumar Thursday, 15 April 2021 11:57 AM

    Currently the corona vaccines given different answer to patients!!!

    RoaringCreek Thursday, 15 April 2021 12:10 PM

    AstraZeneca vaccine is safe for over 60s!

    joe Thursday, 15 April 2021 02:39 PM

    Vaccine politics- The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Vaccine industry is managed by The world’s biggest pharmaceutical companies: Top 5 by revenue 1. Johnson

Add comment

Comments will be edited (grammar, spelling and slang) and authorized at the discretion of Daily Mirror online. The website also has the right not to publish selected comments.

Reply To:

Name - Reply Comment